SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VPHM - Viropharma Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Rocky91/5/2012 5:24:12 PM
   of 2557
 
Increase of sales guidance (or at least new guidance - I thought they were not providing guidance for vanco in the past):

finance.yahoo.com

"For the year 2012, ViroPharma expects the following:

  • Worldwide net product sales are expected to be $600 to $660 million
  • Net U.S. Cinryze sales are expected to be $310 to $330 million .
  • Net Vancocin sales are expected to be $260 to $310 million ; and
  • Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to be $230 to $260 million ."
    • Report TOU ViolationShare This Post
     Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

    HomeMailHotSubjectMarksPeopleMarksKeepersSettings
    Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
    © 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News